FI884013A - Konjugat av cytokiner med immunoglobuliner. - Google Patents

Konjugat av cytokiner med immunoglobuliner. Download PDF

Info

Publication number
FI884013A
FI884013A FI884013A FI884013A FI884013A FI 884013 A FI884013 A FI 884013A FI 884013 A FI884013 A FI 884013A FI 884013 A FI884013 A FI 884013A FI 884013 A FI884013 A FI 884013A
Authority
FI
Finland
Prior art keywords
immunoglobuliner
cytokiner
med
conjugated
conjugates
Prior art date
Application number
FI884013A
Other languages
English (en)
Other versions
FI884013A0 (fi
Inventor
Wussow Peter Von
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI884013A0 publication Critical patent/FI884013A0/fi
Publication of FI884013A publication Critical patent/FI884013A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07GCOMPOUNDS OF UNKNOWN CONSTITUTION
    • C07G99/00Subject matter not provided for in other groups of this subclass
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI884013A 1987-09-02 1988-08-31 Konjugat av cytokiner med immunoglobuliner. FI884013A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH335787 1987-09-02

Publications (2)

Publication Number Publication Date
FI884013A0 FI884013A0 (fi) 1988-08-31
FI884013A true FI884013A (fi) 1989-03-03

Family

ID=4254228

Family Applications (1)

Application Number Title Priority Date Filing Date
FI884013A FI884013A (fi) 1987-09-02 1988-08-31 Konjugat av cytokiner med immunoglobuliner.

Country Status (15)

Country Link
EP (1) EP0305967B1 (fi)
JP (1) JPS6490200A (fi)
KR (1) KR890005137A (fi)
AT (1) ATE88900T1 (fi)
AU (1) AU627694B2 (fi)
DE (1) DE3880766D1 (fi)
DK (1) DK486588A (fi)
ES (1) ES2054753T3 (fi)
FI (1) FI884013A (fi)
IL (1) IL87621A0 (fi)
NO (1) NO883896L (fi)
NZ (1) NZ226005A (fi)
PH (1) PH26813A (fi)
PT (1) PT88385B (fi)
ZA (1) ZA886471B (fi)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3818055A1 (de) * 1988-05-27 1989-11-30 Biotest Pharma Gmbh Kombination aus humanen immunglobulinen und interleukin-2 zur bekaempfung von infektionskrankheiten
GB8820377D0 (en) * 1988-08-26 1988-09-28 Offord R E Chemical compounds
GB8820378D0 (en) * 1988-08-26 1988-09-28 Offord R E Chemical compounds
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
DE3839332A1 (de) * 1988-11-22 1990-05-23 Bayer Ag Verfahren zur herstellung von substituierten 2-chlorpyridinen
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5478804A (en) * 1990-09-19 1995-12-26 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
DK0565620T3 (da) * 1991-01-03 1996-01-22 Salk Inst For Biological Studi Mitotoxin til behandling af karbeskadigelse
PT100090A (pt) * 1991-02-04 1993-07-30 Univ Saskatchewan Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
ATE141515T1 (de) * 1991-02-04 1996-09-15 Univ Saskatchewan Arzneistoffabgabe aus vp6-kapseln
JP3105629B2 (ja) * 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
US7754211B2 (en) 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
EP0833666B1 (en) * 1996-04-10 2003-12-10 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
IT1289608B1 (it) * 1997-02-05 1998-10-15 Angelini Ricerche Spa Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale
CA2312188C (en) 1997-12-08 2010-06-29 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DK1200479T3 (da) 1999-08-09 2006-05-15 Emd Lexigen Res Ct Corp Multiple cytokin-antistof-komplekser
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
CZ304942B6 (cs) 2000-03-31 2015-02-04 Purdue Research Foundation Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
CN1555268B (zh) 2001-07-17 2013-04-03 研究发展基金会 含促调亡蛋白质的治疗剂
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
JP4494977B2 (ja) 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
PT1966238E (pt) 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白
JP5879713B2 (ja) * 2010-12-09 2016-03-08 ソニー株式会社 画像処理装置、および画像処理方法、並びにプログラム
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP4032540A1 (en) 2013-04-19 2022-07-27 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564666A (en) * 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
DK486588D0 (da) 1988-09-01
EP0305967A3 (en) 1990-01-31
NZ226005A (en) 1990-10-26
PH26813A (en) 1992-11-05
EP0305967B1 (de) 1993-05-05
DK486588A (da) 1989-03-03
AU627694B2 (en) 1992-09-03
ES2054753T3 (es) 1994-08-16
IL87621A0 (en) 1989-01-31
ATE88900T1 (de) 1993-05-15
KR890005137A (ko) 1989-05-13
NO883896L (no) 1989-03-03
JPS6490200A (en) 1989-04-06
ZA886471B (en) 1989-04-26
EP0305967A2 (de) 1989-03-08
PT88385A (pt) 1989-07-31
DE3880766D1 (de) 1993-06-09
AU2172588A (en) 1989-03-23
FI884013A0 (fi) 1988-08-31
NO883896D0 (no) 1988-09-01
PT88385B (pt) 1992-10-30

Similar Documents

Publication Publication Date Title
FI884013A0 (fi) Konjugat av cytokiner med immunoglobuliner.
DE3776946D1 (de) Nasale verabreichung von arzneimitteln.
GEP19981482B (en) Use of 1,3 - Oxatiolan Nucleozides Analoges for Treatment of Hepatitis B
NO943901L (no) Fremgangsmåter og preparater for behandling av sykdommer med interferon samtidig som bivirkninger reduseres
AU586860B2 (en) Therapeutical application of phosphonylmethoxyalkyl adenines
DE68929551D1 (de) Menschliche DNase
FI862011A0 (fi) Terapeutiska nukleosider.
DE68914644T2 (de) Verringerung der nebeneffekte bei der krebstherapie.
DK602988D0 (da) Nukleosidderivater med antiviral virkning og laegemiddelpraeparat indeholdende saadanne forbindelser
DE69426334T2 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
NO931413D0 (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
DE68912155T2 (de) Antivirales Kombinationspräparat.
DK68388A (da) Anvendelse af oxochinazolinderivater til fremstilling af laegemidler til behandling af hyperurikaemi
ES2037807T3 (es) Medicamentos que contienen en combinacion interferon y 1-desoxi-piperidinosas, procedimiento para su fabricacion y su aplicacion.
EP0456842A4 (en) Medicinal application of m-csf
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
DK0427633T3 (da) Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer
ES2038578T1 (es) Utilizacion de inmunoglobulinas g humanas, o de fragmentos fc de estas, como medicamento preparatorio para la administracion al hombre de anticuerpos monoclonales.

Legal Events

Date Code Title Description
FD Application lapsed
MM Patent lapsed

Owner name: CIBA-GEIGY AG